Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: A case with long-term follow-up

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • A. Rückert - , University of Freiburg (Author)
  • H. Glimm - , National Center for Tumor Diseases Dresden, University Medical Center Freiburg, University of Freiburg (Author)
  • M. Lübbert - , University of Freiburg (Author)
  • Carsten Grüllich - , University of Freiburg (Author)

Abstract

An association of antiphospholipid antibody syndrome with antibodies directed against either phospholipids or plasma proteins strongly suggest that B-cell dysfunction may be involved in its pathogenesis. Antiphospholipid antibody syndrome with autoimmune cytopenias shows a poor response rate to conventional treatment with anticoagulants, glucocorticosteroids, immunosuppressive agents, intravenous immunoglobulin or plasmapheresis. We report a case of life-threatening antiphospholipid antibody syndrome with Evans syndrome receiving successful multimodal treatment including anti-CD20 monoclonal antibody rituximab with long-term follow-up.

Details

Original languageEnglish
Pages (from-to)757-760
Number of pages4
JournalLupus
Volume17
Issue number8
Publication statusPublished - 2008
Peer-reviewedYes

External IDs

PubMed 18625656

Keywords

ASJC Scopus subject areas

Keywords

  • Antiphospholipid antibody syndrome, Hemolytic anemia, Rituximab, Thrombocytopenia